Highview Capital Management LLC DE Decreases Position in Johnson & Johnson (NYSE:JNJ)

Highview Capital Management LLC DE trimmed its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 4.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,212 shares of the company’s stock after selling 500 shares during the quarter. Johnson & Johnson makes up about 1.4% of Highview Capital Management LLC DE’s portfolio, making the stock its 18th biggest position. Highview Capital Management LLC DE’s holdings in Johnson & Johnson were worth $1,832,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Clarity Wealth Advisors LLC lifted its holdings in shares of Johnson & Johnson by 1.8% during the 3rd quarter. Clarity Wealth Advisors LLC now owns 20,195 shares of the company’s stock valued at $3,299,000 after purchasing an additional 357 shares during the last quarter. Horan Capital Advisors LLC. raised its stake in shares of Johnson & Johnson by 2.0% during the 3rd quarter. Horan Capital Advisors LLC. now owns 18,875 shares of the company’s stock valued at $3,083,000 after buying an additional 373 shares during the last quarter. TAGStone Capital Inc. grew its position in shares of Johnson & Johnson by 0.7% during the 3rd quarter. TAGStone Capital Inc. now owns 21,444 shares of the company’s stock valued at $3,503,000 after acquiring an additional 147 shares during the period. Leisure Capital Management grew its position in shares of Johnson & Johnson by 4.9% during the 3rd quarter. Leisure Capital Management now owns 19,079 shares of the company’s stock valued at $3,117,000 after acquiring an additional 898 shares during the period. Finally, Hendershot Investments Inc. boosted its holdings in Johnson & Johnson by 2.3% in the 3rd quarter. Hendershot Investments Inc. now owns 143,899 shares of the company’s stock worth $23,507,000 after buying an additional 3,221 shares during the last quarter. Institutional investors own 67.94% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Sanford C. Bernstein reduced their price target on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Credit Suisse Group started coverage on shares of Johnson & Johnson in a research note on Thursday, November 17th. They set a “neutral” rating and a $170.00 target price for the company. Raymond James decreased their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research note on Wednesday, October 19th. Atlantic Securities cut their price target on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. Finally, Citigroup boosted their price target on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research note on Monday, December 12th. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $181.75.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of the firm’s stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the transaction, the vice president now directly owns 40,133 shares in the company, valued at $6,869,966.94. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction on Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the transaction, the vice president now directly owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the transaction, the chief financial officer now owns 35,812 shares in the company, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Insiders have sold a total of 233,611 shares of company stock valued at $40,960,735 over the last 90 days. 0.35% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $168.31 on Tuesday. The business’s fifty day moving average price is $176.07 and its two-hundred day moving average price is $171.13. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The stock has a market capitalization of $440.04 billion, a price-to-earnings ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.